Clinical Trail & Therapeutics Research
Pioneering evidence-informed hospital research partnerships, structured integrative cancer supportive care, and ethical clinical evaluation across tertiary healthcare institutions.
Hospital Collaboration Pathway
Nutrason proposes a 4-stage governance framework for clinical evaluation, combining clinical hospital leadership with our analytical formulation design and molecular characterization dossiers.
Clinical Priority
The partner hospital defines the unmet clinical symptom need, specific patient population, and clinical setting (e.g., post-chemo fatigue or neuropathic pain).
Joint Research Plan
Collaboratively establish product dossier, investigational dosing, primary/secondary endpoints, and investigator responsibilities.
Approved Study
Initiate patient recruitment only following Institutional Ethics Committee (IEC) clearance, DCGI/CTRI registration, and site readiness verification.
Evidence Review
Systematically assess safety, tolerability, pharmacokinetic signals, and patient-reported quality-of-life (QoL) outcomes for peer-reviewed publication.
Integrative Cancer Support Process
A structured, non-disruptive palliative and supportive-care pathway designed to run strictly alongside standard medical oncology treatments (chemotherapy, radiotherapy, immunotherapy).
Critical Oncology Research Boundary
Nutrason Bioscience formulations are investigational supportive-care products engineered for symptom relief, convalescence, and palliative comfort. They are NOT a replacement or substitute for surgery, chemotherapy, radiation therapy, immunotherapy, or targeted oncology treatments. No claims of tumor cure or remission are made.
Target Therapeutic Research Domains
Identified areas for evidence-led clinical trials and symptom management under institutional oversight.
Oncology Support & Pain
Evaluation of standardized botanical formulations in managing cancer-related cachexia, generalized palliative discomfort, systemic inflammatory malaise, and treatment-induced fatigue.
Neurology & Neuromuscular
Clinical investigation into plant-derived neuroprotective compounds for chemotherapy-induced peripheral neuropathy (CIPN), spasticity, migraine, and cognitive maintenance in healthy aging.
Sleep, Anxiety & Mood
Restorative sleep architecture trials evaluating GABAergic phytocomplexes (Tagara, Ashwagandha, Jatamansi) in chronic sleep-latency disorders, hospital shift fatigue, and psychological stress.
Metabolic & Digestive Health
Assessing plant alkaloids and bitter principles in preserving intestinal tight junctions, stabilizing gut microbiota, and supporting glucose homeostasis in metabolic syndrome.
Joint & Cartilage Mobility
Double-blind clinical assessments of standardized Shallaki (AKBA) and Hadjod formulations on synovial fluid viscosity, cartilage synthesis, and WOMAC osteoarthritis indices.
Child Nutrition & Healthy Ageing
Developmental nutrition trials for pediatric appetite, height velocity, bone mineral accretion, and antioxidant Rasayana therapy for cellular vitality in the elderly.
Herbs & Phytochemicals in Cancer Care Research
A comprehensive synthesis of published laboratory and clinical research regarding botanical actives, their targeted pathways, and their established supportive roles.
| Botanical Source | Key Active Compound | Cancer-Care Research Role | Preclinical Models Studied | Current Clinical Status |
|---|---|---|---|---|
| Turmeric (Curcuma longa) |
Curcuminoids (Curcumin C3) | Anti-inflammatory, downregulation of NF-κB, COX-2, LOX, and angiogenic signaling. | Breast, colorectal, lung, prostate, hepatic cell lines | Extensively studied adjunct in clinical trials for radiation dermatitis and palliative fatigue. |
| Garlic (Allium sativum) |
Allicin & Organosulphur compounds | Induction of cell cycle arrest, antioxidant enzyme promotion, apoptosis stimulation. | Gastric, colorectal, prostate, breast | Investigational epidemiological and laboratory research; clinical trials ongoing. |
| Ginger (Zingiber officinale) |
Gingerols & Shogaols | Preclinical tumor cell suppression; supportive management of chemotherapy-induced nausea. | Breast, gastrointestinal, melanoma | Mixed clinical trial evidence for anticipatory nausea; valuable palliative digestive adjunct. |
| Green Tea (Camellia sinensis) |
Epigallocatechin gallate (EGCG) | Inhibition of tyrosine kinase receptor signaling, angiogenesis suppression, antioxidant defence. | Breast, lung, prostate, bladder | Extensively studied preclinical candidate; human chemoprevention trials under investigation. |
| Rosemary (Salvia rosmarinus) |
Rosmarinic acid & Carnosic acid | Cell migration suppression, free radical scavenging, modulation of xenobiotic metabolism. | Colon, breast adenocarcinoma | Laboratory research signals; requires defined formulation and safety standardization. |
| Milk Thistle (Silybum marianum) |
Silymarin & Silibinin | Hepatoprotective antioxidant, stabilization of hepatic cell membranes against toxin insult. | Liver, colorectal, prostate | Clinical trials evaluating hepatoprotection during rigorous chemotherapy regimens. |
| Astragalus (Astragalus membranaceus) |
Astragalosides & Polysaccharides | T-cell and NK-cell activation, immune modulation, reduction of treatment-related exhaustion. | Ovarian, lung, leukemia (preclinical) | Used in Asian hospital integrative oncology protocols for quality-of-life support. |
| American Ginseng (Panax quinquefolius) |
Ginsenosides (Rb1, Rg1) | Hypothalamic-pituitary-adrenal axis regulation, reduction of severe cancer-related fatigue. | General fatigue models | Documented multi-center clinical trial evidence (Mayo Clinic) for cancer-related fatigue relief. |
*Literature summary extracted from peer-reviewed scientific databases. Laboratory mechanisms do not constitute therapeutic claims of cancer cure.
Investigational Frontiers: Bacteria-Based Oncology Concepts
Exploring how established biological paradigms (such as intravesical BCG immunotherapy) inform emerging research questions on tumor-microenvironment hypoxia targeting and local bio-delivery.
Established Clinical Paradigm
BCG Immunotherapy: Attenuated Mycobacterium bovis instilled intravesically for non-muscle-invasive bladder cancer, triggering localized immune destruction of malignant urothelial cells.
Tumour Hypoxia Targeting
Solid tumors frequently develop necrotic, poorly oxygenated core zones. Experimental research evaluates facultative/obligate anaerobes that selectively germinate in hypoxic microenvironments.
Local Bio-Delivery Platforms
Engineered non-pathogenic bacterial strains under academic study to deliver therapeutic payloads directly to tumor matrices, sparing healthy surrounding tissues.
Translation Boundaries
Nutrason monitors these horizons as academic literature. Critical translational hurdles include host clearance, bacteremia risks, and reproducible clinical manufacturing standards.
Initiate a Joint Hospital Clinical Study
Nutrason collaborates with medical colleges, tertiary hospitals, and institutional review boards. We provide validated trial formulations, comprehensive analytical dossiers, and clinical data management support.